Skip to main content
The BMJ logoLink to The BMJ
. 2004 Sep 11;329(7466):0.

MAOBIs can benefit patients with Parkinson's disease

PMCID: PMC516635

Monoamine oxidase type B inhibitors (MAOBIs), such as selegiline, may be beneficial in patients with early Parkinson's disease. In a meta-analysis including 17 trials and 3525 patients, Ives and colleagues (p 593) found that patients taking MAOBIs had better total scores, motor scores, and activities of daily living scores on the unified Parkinson's disease rating scale at three months than patients taking placebo; they were also less likely to need additional levodopa or to develop motor fluctuations, and they were not more likely to die or experience side effects.


Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES